Jazz Pharmaceuticals buying more sleep disorder candidates is big news for IHL.
This licensing agreement with Sumitomo Pharma is on a potential drug that’s only currently in Phase 1 trials.
Jazz are paying US$50 million as an upfront payment plus milestone payments of US$1.09 billion. This is just to license the product, not to own the IP.
And remember Jazz bought GW Pharma for US$7.4 billion to leverage Epidiolex, which is much smaller commercial opportunity than obstructive sleep apnea.
IHL-42X could easily be a US$10 billion transaction if you extrapolate even a modest penetration of the annual revenues that CPAP generates globally. Very exciting.
https://www.prnewswire.com/news-rel...oral-orexin-2-receptor-agonist-301537690.html
- Forums
- ASX - By Stock
- IHL
- IHL - INCANNEX - HOLDERS RESEARCH
IHL - INCANNEX - HOLDERS RESEARCH, page-414
-
-
- There are more pages in this discussion • 817 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)